

# **STUDY OF PROTEIN C, PROTEIN S AND ANTITHROMBIN III IN SEPTIC NEWBORNS**

*Thesis*

**Submitted for partial fulfillment  
Of The MD Degree  
Of Pediatrics**

*Submitted by*

**Mohamed Salah Eldin Mohamed Abdel Kader**  
M.B.B. Ch, Msc  
Cairo University

Under supervision of

**DR Amal El Beshlawy**

Professor of Pediatrics  
Faculty of Medicine  
Cairo University

**DR Ibrahim El Araby**

Professor of Pediatrics  
Faculty of Medicine  
Misr University for Science and Technology

**Dr Heba Abou Hussein**

Assistant Professor of Pediatrics  
Faculty of Medicine  
Cairo University

**Dr Heba Hassan Abou-Elew**

Assistant Professor of Clinical Pathology  
Faculty of Medicine  
Cairo University

2007

## **ABSTRACT**

### **Study of protein c, protein s and antithrombin III in septic newborns**

**(KEY WORDS):** Neonatal sepsis , Protein C , Protein S , Antithrombin III, Disseminated intravascular coagulation (DIC), Physiologic inhibition system of coagulation.)

---

Neonatal sepsis is a major cause of neonatal mortality and morbidity. Sepsis greatly affects the coagulation system of the affected neonates. We measured protein c, protein s and antithrombin III levels in thirty septic neonates and thirty normal neonates served as control group. The study revealed the effect of decreased levels of the physiologic inhibition system of coagulation (PISC) including protein c, protein s and antithrombin III on further development of thromboembolic complications in septic neonates, as 30% of the studied cases developed disseminated intravascular coagulation (DIC). Protein C concentrates can act as adjuvant therapy to antibiotics.

# LIST OF TABLES

| Table | Title   | Page |
|-------|---|------|
| 1     | Role of 'contact factors' in integrating body defence mechanisms                | 9    |
| 2     | Haemostasis changes during pregnancy  | 26   |
| 3     | Causes of neonatal thrombocytopenia   | 27   |
| 4     | Bacterial Causes of Systemic Neonatal Infections                                | 51   |
| 5     | Nonbacterial Causes of Systemic Neonatal Infections                             | 53   |
| 6     | Etiologic Agents of Neonatal Pneumonia According to Timing of Acquisition       | 53   |
| 7     | Neonatal Infection by Age of Onset  | 56   |
| 8     | Clinical Manifestations of Transplacental Infections Pathogen                   | 62   |
| 9     | Initial Signs and Symptoms of Infection in Newborn Infants                      | 63   |
| 10    | Manifestations of Neonatal Bacterial Infections                                 | 65   |
| 11    | Serious Systemic Illness in Newborns: Differential Diagnosis of Neonatal Sepsis | 66   |
| 12    | Definitions of SIRS and Sepsis: Pediatric Patients                              | 67   |
| 13    | Evaluation of a Newborn for Infection or Sepsis                                 | 72   |
| 14    | Suggested Dosage Schedules for Antibiotics Used in Newborns                     | 85   |
| 15    | Anthropometric data of the normal and septic neonates                           | 97   |
| 16    | Prenatal risk factors   | 98   |
| 17    | Blood culture results in the study group  | 102  |
| 18    | Associated clinical data  | 103  |
| 19    | Associated complications  | 105  |
| 20    | Statistical analysis of laboratory data of the control group                    | 107  |

|    |   |     |
|----|---|-----|
| 21 | Statistical analysis of laboratory data of the study group                                      | 109 |
| 22 | Comparative analysis of laboratory data between control and study groups                        | 111 |
| 23 | Statistical comparative analysis of the complications of the study group                        | 115 |
| 24 | Statistical comparative analysis of the clinical outcome of the study group                     | 116 |
| 25 | Statistical comparative analysis of the clinical outcome and PISC parameters of the study group | 117 |
| 26 | Antithrombin III Protein S and C in Normal and Septic Newborns                                  | 137 |
| 27 | Prenatal risk factors   | 139 |
| 28 | Associated clinical data of controls and cases  | 141 |
| 29 | Associated complications  | 143 |
| 30 | Hematological parameters  | 145 |
| 31 | Laboratory data in Normal and Septic Newborns   | 147 |

# LIST OF FIGURES

| Figure | Title  | Page |
|--------|--|------|
| 1      | Mechanism of inhibition of coagulation cascade   | 7    |
| 2      | The inhibitors of the blood coagulation system   | 8    |
| 3      | The coagulation cascade  | 8    |
| 4      | The haemostasis network  | 13   |
| 5      | The haemostasis network inhibitors of thrombin generation  | 14   |
| 6      | The haemostasis network: protein C Pathway   | 15   |
| 7      | The haemostasis network: fibrinolysis  | 16   |
| 8      | Blood vessel architecture and functions in haemostasis   | 18   |
| 9      | Modular organization of haemostasis proteins   | 19   |
| 10     | Mechanism of the coagulation disturbance seen in severe sepsis and the actions of activated protein C  | 38   |
| 11     | Pathogenesis of hematogenous transplacental infections   | 45   |
| 12     | Pathways of ascending or intrapartum infection.  | 46   |
| 13     | Factors influencing the balance between health and disease in neonates exposed to a potential pathogen | 47   |
| 14     | Potential pathways from choriodecidual bacterial colonization to preterm delivery                      | 57   |
| 15     | Potential sites of bacterial infection within the uterus   | 58   |
| 16     | Revised perinatal group B streptococcus (GBS) prevention   | 74   |
| 17     | Sex distribution in cases of study group   | 99   |
| 18     | Sex distribution in cases of control group   | 99   |
| 19     | Maternal drug intake in the study group  | 100  |
| 20     | Maternal disease in the study group  | 100  |

| <b>Figure</b> | <b>Title</b>   | <b>Page</b> |
|---------------|--|-------------|
| 21            | Prolonged rupture of membranes (PROM)<br>in the study group  | 101         |
| 22            | Blood culture results in the study group   | 102         |
| 23            | Associated clinical data of the study group  | 104         |
| 24            | Associated complications of the study group  | 106         |
| 25            | Mean values of laboratory data of the control group  | 108         |
| 26            | Mean values of laboratory data of the study group  | 110         |
| 27            | Comparative analysis of Antithrombin III, Protein S and Protein C<br>between control and study groups          | 112         |
| 28            | Comparative analysis of haematological parameters and liver<br>function tests between control and study groups | 113         |
| 29            | Comparative analysis of some sepsis screen parameters between<br>control and study groups                      | 114         |
| 30            | Outcome of the study group   | 116         |
| 31            | Relationship between Protein C% and clinical outcome of the<br>study group                                     | 118         |
| 32            | Relationship between Protein S% and clinical outcome of the<br>study group                                     | 119         |
| 33            | Relationship between AT III % and clinical outcome of the study<br>group                                       | 120         |

# **LIST OF ABBREVIATIONS**

|                  |  |
|------------------|--|
| A .....          | Activated factor                             |
| ALT.....         | Alanine aminotransferase                     |
| APC .....        | Activated protein C                          |
| AST .....        | Aspartate aminotransferase                   |
| ATIII.....       | Antithrombin III                             |
| DIC .....        | Disseminated intravascular coagulation       |
| Drot AA.....     | Drotrecogin alpha activated                  |
| EPCP .....       | Endothelial cell protein C receptor          |
| F... ..          | Factor                                       |
| FDP... ..        | Fibrin degradation product                   |
| GBS... ..        | Group B streptococcus                        |
| HB .....         | Haemoglobin                                  |
| HCT.....         | Haematocrite                                 |
| NEC.....         | Necrotizing enterocolitis                    |
| PC.....          | Protein C                                    |
| P.Fulminans..... | Purpura Fulminans                            |
| PS.....          | Protein S                                    |
| PISC.....        | Physiologic inhibition system of coagulation |
| PROM.....        | Prolonged rupture of membranes               |
| PT .....         | Prothrombin time                             |
| PTT.....         | Partial activated thromboplastin time        |
| Rh-APC.....      | Recombinant human activated protein c        |
| TM .....         | Thrombomodulin                               |
| TPF .....        | Tissue factor pathway                        |





# INTRODUCTION

---

The perinatal period is associated with an increased incidence of thromboembolic complications, which may occur in both the maternal and the fetal circulation in otherwise normal and healthy adults and fetuses, and this may be related to the activation of the coagulation system at the time of parturition. The risk of these complications is generally much higher in neonates, who have decreased activity of the physiologic inhibition system of coagulation (PISC), including protein C, protein S, and antithrombin III in comparison with adults, thus predisposing neonates to thromboembolic complications (*Malida et al, 2002*).

The hemostatic system of the fetus and of the neonate is dynamic. Coagulation and inhibitory factors of coagulation are progressively synthesized by the fetus beginning mainly after 34 weeks of gestation and into the first hours following delivery, guaranteeing the presence of a sufficient hemostatic balance at birth. At term, most fetal plasma factors of coagulation, including vitamin K-dependent factors, contact factors and the physiologic inhibition system of coagulation (PISC), are obviously immature and have not yet reached adult plasma concentrations (*Malida et al, 2002*).

Sepsis has emerged as one of the most crucial factors influencing the mortality and morbidity of the newborn and preterm infant in intensive care units (*Kreuz et al, 1999*).

A number of life threatening pathologic processes including sepsis, septic shock, hypoxia, acidosis, tissue necrosis and endothelial damage may trigger DIC (*Behrman and Kleigman, 2004*). In these newborns, sepsis and septic shock, as a progressive state of poor tissue perfusion, leads to severe metabolic derangements and organ failure during overwhelming infection. The underlying pathophysiology is a combination of irreversible hypotension and obstructed flow because of microthrombus formation in the capillary system (*Bone, 1994*). Whereas the former is mainly a direct response to endotoxin, microcirculatory thrombosis is the result of multiple pathway activation as a systemic response to infection, termed systemic inflammatory response syndrome (SIRS) (*Suffredini et al., 1990*).

Because of hypoxia which has been proven to decrease the levels of protein C, protein S and antithrombin III (*El-Beshlawy et al., 2004*), physiological cardiopulmonary overload, and other neonatal disorders, newborns and preterm infants are predisposed to disturbances of the peripheral circulation. Therefore the vascular endothelium of these patients is especially vulnerable in maintaining hemostasis, leading to early association of sepsis and DIC (*Leithauser et al., 1996*).

There is a large body of evidence that the hemostatic system of the newborns and preterm infant is generally shifted towards hypercoagulation. During sepsis this hypercoagulability is further exacerbated by affecting the coagulation and the inhibitory factors of

coagulation including protein C, protein S and antithrombin III (*Roman et al., 1992*).

Sepsis is considered an acute stressor that was found to alter coagulation system equilibrium (*Andrew, 1997*).

## **AIM OF THE WORK**

---

This study aims to clarify the effect of sepsis on the physiologic inhibition system of coagulation including protein C, protein S and antithrombin III and their effect on thromboembolic accidents of septic newborns.

# **REVIEW OF LITERATURE**

---


## **ROLE OF PROTEIN C, PROTEIN S AND ANTITHROMBIN III IN HAEMOSTASIS IN THE PEDIATRIC AND NEONATEAL AGE GROUP**

Haemostasis is one of a number of protective processes that have evolved in order to maintain a stable physiology. It has many features in common with (and to some extent interacts with) other defence mechanisms in the body, such as the immune system and the inflammatory response. These links are most clearly seen in ancient species such as the horseshoe crab (*Limulus polyphemus*), where a primitive 'coagulation' pathway is initiated by entry of endotoxin into the haemolymph. Vestiges of this process still exist in humans and may give rise to serious clinical consequences. For example, disseminated intravascular coagulation (DIC) can be initiated by Gram-negative septicemia. However, consequent upon the development of a high-pressure blood circulatory system, extra components have evolved and have resulted in a complex, highly integrated process in all vertebrates. Indeed, recent analysis of the haemostatic network in bony fish suggests that the network in its entirety evolved over 430 million years ago, prior to the divergence of bony fish from tetrapods (**Dahlback and Villoutreix, 2003**).

The high blood pressure generated on the arterial side of vertebrate circulation requires a powerful, almost instantaneous but strictly localized

procoagulant response in order to minimize blood loss from sites of vascular injury without compromising blood flow generally. Systemic anticoagulant and clot-dissolving components have also evolved to prevent extension of the procoagulant response beyond the vicinity of vascular injury resulting in unwanted thrombus formation in the slow, sometimes intermittent, blood flow in the veins. The resultant haemostatic system is thus a complex mosaic of activating or inhibitory feedback or feed-forward pathways, integrating its five major components (blood vessels, blood platelets, coagulation factors, coagulation inhibitors and fibrinolytic elements). Furthermore, links between haemostasis and other elements of the body's overall defence response, such as the complement and kinin-generating processes and phagocytosis, must also be considered **(Dahlback and Villoutreix, 2003)**.

In the most simplistic terms, blood coagulation occurs when the enzyme thrombin is generated and proteolyses soluble plasma fibrinogen, forming the insoluble fibrin polymer, or clot; this provides the physical consolidation of vessel wound repair following injury. Haemostasis' refers more widely to the process whereby blood coagulation is initiated and terminated in a tightly regulated fashion, together with the removal (or fibrinolysis) of the clot as part of vascular remodelling; as such, haemostasis describes the global process by which vessel integrity and patency are maintained over the whole organism, for its lifetime **(Dahlback and Villoutreix, 2003)**.



**Fig (1): Mechanism of inhibition of coagulation cascade from (Kemball-Cook and Tuddenham et al.: Normal haemostasis :In Postgraduate Haematology edited by A. Victor Hoffbrand, Daniel Catovsky, Edward G.D. Tuddenham: Fifth Edition, 2006.)**